T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

A patient with progressive metastatic pancreatic cancer was treated with a single infusion of
16.2× 109 autologous T cells that had been genetically engineered to clonally express two …

Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …

Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Immunological memory is an important evolutionary trait that improves host survival upon
reinfection. Memory is a characteristic recognized within both the innate and adaptive arms …

Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …

The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in
the past few decades. As of today, there are six CAR T cell products that have been …